Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.8101
-0.4399-35.19%
Pre-market: 0.83100.0209+2.58%07:36 EDT
Volume:15.13M
Turnover:13.30M
Market Cap:66.80M
PE:-0.47
High:1.01
Open:0.9990
Low:0.8084
Close:1.25
Loading ...

Sutro Biopharma Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Sutro Biopharma (STRO) Receives a Buy from Truist Financial

TIPRANKS
·
15 Nov 2024

Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Nov 2024

Sutro Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
14 Nov 2024

Sutro Biopharma Q3 EPS $(0.59) Beats $(0.73) Estimate, Sales $8.52M Miss $15.25M Estimate

Benzinga
·
14 Nov 2024

BRIEF-Sutro Biopharma Q3 Revenue USD 8.52 Million

Reuters
·
14 Nov 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

THOMSON REUTERS
·
14 Nov 2024

Sutro Biopharma Q3 Operating Expenses USD 76.439 Million

THOMSON REUTERS
·
14 Nov 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire
·
14 Nov 2024

Sutro Biopharma Inc expected to post a loss of 73 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

GlobeNewswire
·
05 Nov 2024

Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial

MT Newswires Live
·
01 Nov 2024

BRIEF-Sutro Biopharma Announces Initiation Of The Registration-Enabling REFRαME-P1 Trial With Luvelta For Pediatric Patients With CBF/GLIS AML

Reuters
·
01 Nov 2024

Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml

THOMSON REUTERS
·
01 Nov 2024

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

GlobeNewswire
·
01 Nov 2024